Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-20-009683
Filing Date
2020-08-06
Accepted
2020-08-06 16:30:59
Documents
49
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 6-K prqr-20200630x6k.htm 6-K 26116
2 EX-10.1 prqr-20200630ex10151c195.htm EX-10.1 118287
3 EX-99.1 prqr-20200630ex9918b6db3.htm EX-99.1 541998
4 EX-99.2 prqr-20200630ex992962b70.htm EX-99.2 575646
  Complete submission text file 0001558370-20-009683.txt   2781340

Data Files

Seq Description Document Type Size
5 EX-101.INS prqr-20200630.xml EX-101.INS 238111
6 EX-101.SCH prqr-20200630.xsd EX-101.SCH 37258
7 EX-101.CAL prqr-20200630_cal.xml EX-101.CAL 34539
8 EX-101.DEF prqr-20200630_def.xml EX-101.DEF 64391
9 EX-101.LAB prqr-20200630_lab.xml EX-101.LAB 243680
10 EX-101.PRE prqr-20200630_pre.xml EX-101.PRE 158096
Mailing Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK
Business Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK 31 88 166 7000
ProQR Therapeutics N.V. (Filer) CIK: 0001612940 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36622 | Film No.: 201082183
SIC: 2834 Pharmaceutical Preparations